Elevance Health, Inc. (ELV)

In the past six months, Elevance Health's stock has been influenced by several key events. In the fourth quarter of 2025, the company reported operating revenue of $49.3 billion, an increase of 10% compared to the prior year quarter. Entering 2026, Elevance Health delivered first-quarter results ahead of expectations, with operating revenue of $49.5 billion, up 1.5% from Q1 2025. The company subsequently raised its full-year 2026 adjusted EPS guidance to at least $26.75. An unresolved government investigation into Medicare Advantage risk-adjustment coding irregularities has been a key investor concern. Analyst ratings have varied, with some downgrades in price targets despite overall positive sentiment from strong Q1 results.

Demand for Elevance Health's products and services exhibits clear seasonality. A significant surge in sign-ups occurs during open enrollment periods, which typically run from November to January for marketplace Affordable Care Act (ACA) plans. Medical spending is generally highest in the first quarter of the year and lowest in the fourth quarter. Winter months can also bring an increase in medical claims due to a surge in illnesses.

Elevance Health, Inc. is an American health insurance company focused on improving lives and communities by simplifying healthcare, serving approximately 47-48 million medical members nationwide. The company offers a comprehensive portfolio of products and services, including medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. It also provides pharmacy benefit management (PBM) services, digital health solutions, life insurance, and supplemental health insurance benefits, operating through affiliated brands such as Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon.

Headquartered in Indianapolis, Indiana, Elevance Health primarily focuses on the U.S. market. It operates as the licensee for the Blue Cross Blue Shield Association in 14 states and extends its reach through government-sponsored programs like Medicaid and Medicare Advantage plans, including operations in California, Florida, Georgia, Indiana, Kentucky, Missouri, New York, Ohio, Texas, and Puerto Rico. Elevance Health's global presence is further extended through its Business Process Outsourcing (BPO)/Shared Services subsidiary, Carelon Global Solutions, which operates sites in India, Puerto Rico, the Philippines, and the United States.

Elevance Health maintains a commanding presence in the health insurance market through its strong brand recognition and extensive customer base. Its exclusive right to market Blue Cross Blue Shield products in its most significant markets further solidifies its brand. However, in 2025, Elevance subsidiaries Carelon Behavioral Health and Anthem Blue Cross and Blue Shield were subject to lawsuits alleging that they operate "ghost networks."

Elevance Health's ownership is widely dispersed, with institutional shareholders collectively holding approximately 91-93% of the company's stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors and retail investors hold a smaller percentage of the shares, typically around 3-4%. Insider ownership is relatively low, around 2-3%, with insiders generally selling more than buying in recent periods.